Michael Becka

6.7k total citations · 5 hit papers
51 papers, 5.2k citations indexed

About

Michael Becka is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Hematology. According to data from OpenAlex, Michael Becka has authored 51 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Cardiology and Cardiovascular Medicine, 16 papers in Internal Medicine and 9 papers in Hematology. Recurrent topics in Michael Becka's work include Atrial Fibrillation Management and Outcomes (24 papers), Venous Thromboembolism Diagnosis and Management (16 papers) and Blood Coagulation and Thrombosis Mechanisms (9 papers). Michael Becka is often cited by papers focused on Atrial Fibrillation Management and Outcomes (24 papers), Venous Thromboembolism Diagnosis and Management (16 papers) and Blood Coagulation and Thrombosis Mechanisms (9 papers). Michael Becka collaborates with scholars based in Germany, United States and Italy. Michael Becka's co-authors include Dagmar Kubitza, Wolfgang Mueck, Michael Zuehlsdorf, Barbara Voith, Georg Wensing, Jan Stampfuss, Angelika Roth, Michael Voelker, William Rosenberg and Alastair D. Burt and has published in prestigious journals such as Blood, Gastroenterology and Hepatology.

In The Last Decade

Michael Becka

51 papers receiving 5.0k citations

Hit Papers

Serum markers detect the presence of liver fibrosis: A co... 2004 2026 2011 2018 2004 2005 2005 2013 2013 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Serum markers detect the presence of liver fibrosis: A cohort study
    2004 830 citations William Rosenberg, Michael Becka et al. profile →
  2. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
    2005 512 citations Dagmar Kubitza, Michael Becka et al. Clinical Pharmacology & Therapeutics profile →
  3. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
    2005 507 citations Dagmar Kubitza, Michael Becka et al. profile →
  4. Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
    2013 429 citations Wolfgang Mueck, Jan Stampfuss et al. Clinical Pharmacokinetics profile →
  5. Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects
    2013 315 citations Wolfgang Mueck, Dagmar Kubitza et al. British Journal of Clinical Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Becka Germany 25 3.6k 2.8k 968 694 608 51 5.2k
Gerhard Nehmiz Germany 22 1.5k 0.4× 909 0.3× 803 0.8× 807 1.2× 135 0.2× 43 2.8k
Dagmar Kubitza Germany 38 5.0k 1.4× 3.8k 1.4× 627 0.6× 72 0.1× 1.0k 1.7× 82 6.6k
S Coccheri Italy 29 2.2k 0.6× 1.8k 0.6× 430 0.4× 86 0.1× 969 1.6× 148 4.2k
Wolfgang Mueck Germany 31 4.2k 1.1× 3.0k 1.1× 225 0.2× 69 0.1× 624 1.0× 68 5.1k
Sylvia Haas Germany 43 7.2k 2.0× 6.4k 2.3× 623 0.6× 82 0.1× 1.2k 2.0× 209 9.1k
John F. Paolini United States 32 8.1k 2.2× 3.8k 1.4× 1.6k 1.6× 57 0.1× 296 0.5× 90 10.5k
Joanne van Ryn Germany 39 3.8k 1.0× 2.8k 1.0× 546 0.6× 35 0.1× 997 1.6× 121 5.6k
Robert C. Gosselin United States 38 2.1k 0.6× 1.9k 0.7× 357 0.4× 30 0.0× 1.1k 1.8× 150 4.8k
Frank LaCreta United States 38 1.7k 0.5× 863 0.3× 373 0.4× 102 0.1× 177 0.3× 110 4.5k
Cesare Manotti Italy 19 1.7k 0.5× 1.4k 0.5× 242 0.3× 29 0.0× 626 1.0× 60 2.7k

Countries citing papers authored by Michael Becka

Since Specialization
Citations

This map shows the geographic impact of Michael Becka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Becka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Becka more than expected).

Fields of papers citing papers by Michael Becka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Becka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Becka. The network helps show where Michael Becka may publish in the future.

Co-authorship network of co-authors of Michael Becka

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Becka. A scholar is included among the top collaborators of Michael Becka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Becka. Michael Becka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kubitza, Dagmar, Stefan Willmann, Michael Becka, et al.. (2018). Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study. Thrombosis Journal. 16(1). 31–31. 29 indexed citations
2.
Kreutz, Reinhold, Pontus B. Persson, Dagmar Kubitza, et al.. (2017). Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study. Journal of Thrombosis and Haemostasis. 15(10). 2017–2028. 38 indexed citations
3.
Nagelschmitz, Johannes, et al.. (2014). The novel elastase inhibitor BAY 85-8501: Bioavailability and Food effect study to evaluate pharmacokinetics of tablet formulations. European Respiratory Journal. 44(Suppl 58). P1511–P1511. 2 indexed citations
4.
Nagelschmitz, Johannes, et al.. (2014). The novel elastase inhibitor BAY 85-8501: First-in-man study to evaluate safety, tolerability and pharmacokinetics in healthy male subjects. European Respiratory Journal. 44(Suppl 58). P1510–P1510. 2 indexed citations
5.
Kubitza, Dagmar, Michael Becka, Angelika Roth, & Wolfgang Mueck. (2013). The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban—An Oral, Direct Factor Xa Inhibitor. The Journal of Clinical Pharmacology. 53(3). 249–255. 90 indexed citations
6.
Kubitza, Dagmar, Michael Becka, Stephan Schwers, & Barbara Voith. (2013). Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects. Clinical Pharmacology in Drug Development. 2(3). 270–277. 25 indexed citations
7.
Wolzt, Michael, Ghazaleh Gouya, Stylianos Kapiotis, et al.. (2013). Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. Thrombosis Research. 132(2). 240–247. 12 indexed citations
8.
Mueck, Wolfgang, Jan Stampfuss, Dagmar Kubitza, & Michael Becka. (2013). Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban. Clinical Pharmacokinetics. 53(1). 1–16. 429 indexed citations breakdown →
9.
Kubitza, Dagmar, Michael Becka, Wolfgang Mueck, et al.. (2010). Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. British Journal of Clinical Pharmacology. 70(5). 703–712. 334 indexed citations
10.
Graff, Jochen, Nils von Hentig, Frank Misselwitz, et al.. (2007). Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity1. The Journal of Clinical Pharmacology. 47(11). 1398–1407. 118 indexed citations
11.
Mueck, Wolfgang, Michael Becka, Dagmar Kubitza, Barbara Voith, & Michael Zuehlsdorf. (2007). Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban an oral, direct Factor Xa inhibitor in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics. 45(6). 335–344. 142 indexed citations
12.
Kubitza, Dagmar, Michael Becka, Michael Zuehlsdorf, & Wolfgang Mueck. (2006). Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects. The Journal of Clinical Pharmacology. 46(5). 549–558. 198 indexed citations
13.
Kubitza, Dagmar, Michael Becka, Wolfgang Mueck, & Michael Zuehlsdorf. (2006). Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen. British Journal of Clinical Pharmacology. 63(4). 469–476. 130 indexed citations
14.
Kubitza, Dagmar, Michael Becka, Barbara Voith, Michael Zuehlsdorf, & Georg Wensing. (2005). Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clinical Pharmacology & Therapeutics. 78(4). 412–421. 512 indexed citations breakdown →
15.
Haase, Claus G., Michael Becka, J. Kuhlmann, & Georg Wensing. (2005). Influences of caffeine, acetazolamide and cognitive stimulation on cerebral blood flow velocities. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 29(4). 549–556. 6 indexed citations
16.
Kubitza, Dagmar, Michael Becka, Georg Wensing, Barbara Voith, & Michael Zuehlsdorf. (2003). Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects. Blood. 102(11). 811. 19 indexed citations
17.
Rosenberg, William, Alastair D. Burt, Stefan G. Hübscher, et al.. (2001). Serum markers predict liver fibrosis. Hepatology. 4 indexed citations
18.
19.
Rosenberg, William, et al.. (2000). Automated assays of serum markers of liver fibrosis predict histological hepatic fibrosis.. UCL Discovery (University College London). 5 indexed citations
20.
Steinke, Wolfram, Michael Becka, Rudolf Binder, et al.. (2000). Quantitative Distribution Studies in Animals: Cross-Validation of Radioluminography versus Liquid-Scintillation Measurement. Regulatory Toxicology and Pharmacology. 31(2). S33–S43. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerhard Nehmiz Breakdown of academic impact, for papers by Dagmar Kubitza Breakdown of academic impact, for papers by S Coccheri Breakdown of academic impact, for papers by Wolfgang Mueck Breakdown of academic impact, for papers by Sylvia Haas Breakdown of academic impact, for papers by John F. Paolini Breakdown of academic impact, for papers by Joanne van Ryn Breakdown of academic impact, for papers by Robert C. Gosselin Breakdown of academic impact, for papers by Frank LaCreta Breakdown of academic impact, for papers by Cesare Manotti
Rankless by CCL
2026